{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:48:36Z","timestamp":1769586516436,"version":"3.49.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T00:00:00Z","timestamp":1538784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T00:00:00Z","timestamp":1538784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11938-018-0200-4","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T03:46:22Z","timestamp":1538797582000},"page":"548-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Update on Vaccinating the Patient With Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"16","author":[{"given":"Jennifer","family":"Coukos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,6]]},"reference":[{"issue":"8","key":"200_CR1","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","volume":"101","author":"GY Melmed","year":"2006","unstructured":"Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834\u201340.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"200_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ibd.20266","volume":"14","author":"L Selby","year":"2008","unstructured":"Selby L, Kane S, Wilson J, Balla P, Riff B, Bingcang C, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008;14(2):253\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"200_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","volume":"112","author":"FA Farraye","year":"2017","unstructured":"\u2022 Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241\u201358 These guidelines by the ACG address the safety and appropriate timing of vaccinations in IBD patients. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system is used to evaluate the strength of each recommendation.","journal-title":"Am J Gastroenterol"},{"issue":"RR-15","key":"200_CR4","first-page":"1","volume":"55","author":"AT Kroger","year":"2006","unstructured":"Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2006;55(RR-15):1\u201348.","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"200_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/ajg.2009.733","volume":"105","author":"SK Wasan","year":"2010","unstructured":"Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105(6):1231\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"200_CR6","first-page":"540","volume":"12","author":"J Reich","year":"2016","unstructured":"\u2022 Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12(9):540\u20136 In addition to outlining appropriate vaccinations, this article discusses strategies for improving vaccination rates among patients with IBD.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"3","key":"200_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"L Rubin","year":"2014","unstructured":"Rubin L, Levin M, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309\u201318.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"200_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/flgastro-2014-100548","volume":"7","author":"K Greveson","year":"2016","unstructured":"\u2022 Greveson K, Shepherd T, Mulligan JP, et al. Travel health and pretravel preparation in the patient with inflammatory bowel disease. Frontline Gastroenterol. 2016;7(1):60\u20135 This study showed that only a minority of patients with IBD seek pretravel advice and many providers do not feel comfortable providing this advice. A majority of clinicians would refer to a specialty clinic regardless of their confidence level. This article suggests that there still exists a need for greater education of patients with IBD prior to foreign travel.","journal-title":"Frontline Gastroenterol"},{"issue":"12","key":"200_CR9","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1002\/ibd.21667","volume":"17","author":"SK Wasan","year":"2011","unstructured":"Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17(12):2536\u201340.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"200_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ibd.21668","volume":"18","author":"JH Yeung","year":"2012","unstructured":"Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 2012;18(1):34\u201340.","journal-title":"Inflamm Bowel Dis"},{"issue":"1100","key":"200_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/postgradmedj-2016-134266","volume":"93","author":"GE Gurvits","year":"2017","unstructured":"\u2022 Gurvits GE, Lan G, Tan A, Weissman A. Vaccination practices in patients with inflammatory bowel disease among general internal medicine physicians in the USA. Postgrad Med J. 2017;93(1100):333\u20137 This study demonstrates that primary care physicians have a poor understanding and comfort in regards to appropriate vaccinations for patients with IBD.","journal-title":"Postgrad Med J"},{"issue":"11","key":"200_CR12","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/ajg.2015.162","volume":"110","author":"KR Christensen","year":"2015","unstructured":"Christensen KR, Steenholdt C, Buhl SS, Ainsworth MA, Thomsen O\u00d8, Brynskov J. Systematic information to health-care professionals about vaccination guidelines improves adherence in patients with inflammatory bowel disease in anti-TNF\u03b1 therapy. Am J Gastroenterol. 2015;110(11):1526\u201332.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"200_CR13","first-page":"396","volume":"11","author":"JS Reich","year":"2015","unstructured":"Reich JS, Miller HL, Wasan SK, Noronha A, Ardagna E, Sullivan K, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015;11(6):396\u2013401.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"2","key":"200_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/01.MIB.0000437737.68841.87","volume":"20","author":"SK Wasan","year":"2014","unstructured":"Wasan SK, Calderwood AH, Long MD, Kappelman MD, Sandler RS, Farraye FA. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis. 2014;20(2):246\u201350.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"200_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/00054725-200409000-00028","volume":"10","author":"BE Sands","year":"2004","unstructured":"Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):677\u201392.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"200_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/ibd.20943","volume":"15","author":"GY Melmed","year":"2009","unstructured":"Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009;15(9):1410\u20136.","journal-title":"Inflamm Bowel Dis"},{"key":"200_CR17","doi-asserted-by":"publisher","unstructured":"\u2022 Tinsley A, Navabi S, Williams ED, et al. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018; https:\/\/doi.org\/10.1093\/ibd\/izy243 This is the first study designed to evaluate the incidence and severity of influenza in patients with IBD.","DOI":"10.1093\/ibd\/izy243"},{"key":"200_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.15585\/mmwr.mm6722a5","volume":"67","author":"LA Grohskopf","year":"2018","unstructured":"\u2022 Grohskopf LA, Sokolow LZ, Fry AM, et al. Update: ACIP recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4)\u2014United States, 2018\u201319 influenza season. MMWR Morb Mortal Wkly Rep. 2018;67:643\u20135 The updated ACIP guideline states that despite changing recommendation over the past few years, the live attenuated influenza vaccine (LAIV4) is an effective option for flu protection during the 2018\u20132019 season.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"200_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.crohns.2012.05.011","volume":"7","author":"G Andrisani","year":"2013","unstructured":"Andrisani G, Frasca D, Romero M, Armuzzi A, Felice C, Marzo M, et al. Immune response to influenza a\/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-\u03b1 agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013;7(4):301\u20137.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"200_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/MIB.0000000000000615","volume":"22","author":"J DeBruyn","year":"2016","unstructured":"\u2022 DeBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638\u201347 Response to influenza vaccine is reduced in patients on infliximab. However, this study demonstrated that the timing of vaccine relative to infliximab infusion did not affect the achievement of serologic protection.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"200_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/ajg.2011.320","volume":"107","author":"GY Melmed","year":"2012","unstructured":"Melmed GY. Vaccinations while on thiopurines: some protection is better than none. Am J Gastroenterol. 2012;107(1):141\u20132.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"200_CR22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s00535-015-1042-7","volume":"50","author":"H Matsumoto","year":"2015","unstructured":"Matsumoto H, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, et al. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial. J Gastroenterol. 2015;50(8):876\u201386.","journal-title":"J Gastroenterol"},{"issue":"2","key":"200_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/ajg.2012.406","volume":"108","author":"MD Long","year":"2013","unstructured":"Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"200_CR24","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/ajg.2015.284","volume":"110","author":"B Kants\u00f8","year":"2015","unstructured":"Kants\u00f8 B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977-2013. Am J Gastroenterol. 2015;110(11):1582\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"34","key":"200_CR25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","volume":"64","author":"M Kobayashi","year":"2015","unstructured":"Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"200_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ajg.2009.523","volume":"105","author":"GY Melmed","year":"2010","unstructured":"Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(1):148\u201354.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"200_CR27","first-page":"952","volume":"34","author":"S Visvanathan","year":"2007","unstructured":"Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol. 2007;34(5):952\u20137.","journal-title":"J Rheumatol"},{"issue":"38","key":"200_CR28","doi-asserted-by":"publisher","first-page":"6167","DOI":"10.3748\/wjg.v12.i38.6167","volume":"12","author":"J Bhatia","year":"2006","unstructured":"Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12(38):6167\u201371.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"200_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","volume":"103","author":"S Kane","year":"2008","unstructured":"Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"200_CR30","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","volume":"21","author":"JR Allegretti","year":"2015","unstructured":"Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? A meta-analysis. Inflamm Bowel Dis. 2015;21(5):1089\u201397.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"200_CR31","first-page":"300","volume":"64","author":"E Petrosky","year":"2015","unstructured":"Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"200_CR32","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","volume":"65","author":"E Meites","year":"2016","unstructured":"\u2022 Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination\u2014updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405\u20138 The ACIP guidelines continue to recommend a 3-dose vaccine series for HPV if the vaccine is given at ages 15 through 26 years and for immunocompromised patients. However, the updated guidelines now support a 2-dose series if the vaccine is given at ages 9 through 14 years.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"200_CR33","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1097\/MIB.0b013e318281341b","volume":"19","author":"DL Jacobson","year":"2013","unstructured":"Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1441\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"200_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ibd.21284","volume":"16","author":"JK Hou","year":"2010","unstructured":"Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(6):925\u201332.","journal-title":"Inflamm Bowel Dis"},{"issue":"20","key":"200_CR35","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.3748\/wjg.14.3201","volume":"14","author":"YF Tolentino","year":"2008","unstructured":"Tolentino YF, Fogaca HS, Zaltman C, et al. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital. World J Gastroenterol. 2008;14(20):3201\u20136.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"200_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/rmv.322","volume":"11","author":"L Xunrong","year":"2001","unstructured":"Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. Rev Med Virol. 2001;11(5):287\u201399.","journal-title":"Rev Med Virol"},{"issue":"6","key":"200_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","volume":"90","author":"R P\u00e9rez-Alvarez","year":"2011","unstructured":"P\u00e9rez-Alvarez R, D\u00edaz-Lagares C, Garc\u00eda-Hern\u00e1ndez F, Lopez-Roses L, Brito-Zer\u00f3n P, P\u00e9rez-de-Lis M, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90(6):359\u201371.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"200_CR38","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/gut.2004.040675","volume":"53","author":"M Esteve","year":"2004","unstructured":"Esteve M, Saro C, Gonz\u00e1lez-Huix F, Suarez F, Forn\u00e9 M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis. Gut. 2004;53(9):1363\u20135.","journal-title":"Gut"},{"issue":"3","key":"200_CR39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2893.2012.01643.x","volume":"20","author":"F Morisco","year":"2013","unstructured":"Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, et al. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat. 2013;20(3):200\u20138.","journal-title":"J Viral Hepat"},{"issue":"7","key":"200_CR40","first-page":"1624","volume":"30","author":"M Michel","year":"2003","unstructured":"Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still\u2019s disease. J Rheumatol. 2003;30(7):1624\u20135.","journal-title":"J Rheumatol"},{"issue":"20","key":"200_CR41","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.vaccine.2017.03.080","volume":"35","author":"HY Jiang","year":"2017","unstructured":"\u2022 Jiang HY, Wang SY, Deng M, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017;35(20):2633\u201341 This meta-analysis demonstrated poor serological response to hepatitis B vaccine in patients with IBD and provided several predictive variables for level of immune response.","journal-title":"Vaccine"},{"issue":"22","key":"200_CR42","doi-asserted-by":"publisher","first-page":"e940","DOI":"10.1097\/MD.0000000000000940","volume":"94","author":"C Cekic","year":"2015","unstructured":"Cekic C, Aslan F, Krc A, et al. Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel disease. Medicine (Baltimore). 2015;94(22):e940.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"200_CR43","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10620-011-1980-8","volume":"57","author":"ME Altun\u00f6z","year":"2012","unstructured":"Altun\u00f6z ME, Senate\u015f E, Ye\u015fil A, et al. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci. 2012;57(4):1039\u201344.","journal-title":"Dig Dis Sci"},{"issue":"15","key":"200_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.15585\/mmwr.mm6715a5","volume":"67","author":"S Schillie","year":"2018","unstructured":"\u2022 Schillie S, Harris A, Link-Gelles R, et al. Recommendations of the advisory committee on immunization practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455\u20138 In July 2017, the FDA approved a new 2-dose hepatitis B vaccine (Heplisav-B, Dynavax) which can be given over one month compared to the 3-dose series over 6 months required for the older hepatitis B vaccines.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"200_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1086\/589722","volume":"198","author":"K Cardell","year":"2008","unstructured":"Cardell K, Akerlind B, S\u00e4llberg M, Fryd\u00e9n A. Excellent response rate to a double dose of the combined hepatitis a and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis. 2008;198(3):299\u2013304.","journal-title":"J Infect Dis"},{"issue":"4","key":"200_CR46","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/MPG.0b013e31827dd87d","volume":"56","author":"N Urganci","year":"2013","unstructured":"Urganci N, Kalyoncu D. Immunogenecity of hepatitis a and B vaccination in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56(4):412\u20135.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"200_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/01.MIB.0000437736.91712.a1","volume":"20","author":"SH Park","year":"2014","unstructured":"Park SH, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, et al. Efficacy of hepatitis a vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(1):69\u201374.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"200_CR48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/ibd.21465","volume":"17","author":"A Radzikowski","year":"2011","unstructured":"Radzikowski A, Banaszkiewicz A, \u0141azowska-Przeorek I, Grzybowska-Chlebowczyk U, Wo\u015b H, Pytrus T, et al. Immunogenecity of hepatitis a vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(5):1117\u201324.","journal-title":"Inflamm Bowel Dis"},{"key":"200_CR49","doi-asserted-by":"publisher","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","volume":"66","author":"ME Patton","year":"2017","unstructured":"Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine\u2014advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:509\u201313.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-2","key":"200_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","volume":"67","author":"JL Liang","year":"2018","unstructured":"Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2018;67(RR-2):1\u201344.","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"200_CR51","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/s10620-018-5043-2","volume":"63","author":"F Caldera","year":"2018","unstructured":"\u2022 Caldera F, Saha S, Wald A, et al. Lower sustained diphtheria and pertussis antibody concentrations in inflammatory bowel disease patients. Dig Dis Sci. 2018;63(6):1532\u201340 This study is first to evaluate sustained protection against diphtheria and pertussis in patients with IBD.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"200_CR52","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/MIB.0000000000000448","volume":"21","author":"S Dezfoli","year":"2015","unstructured":"Dezfoli S, Horton HA, Thepyasuwan N, Berel D, Targan SR, Vasiliauskas EA, et al. Combined immunosuppression impairs immunogenicity to tetanus and pertussis vaccination among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1754\u201360.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"200_CR53","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","volume":"4","author":"G Gupta","year":"2006","unstructured":"Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(12):1483\u201390.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"200_CR54","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/apt.12182","volume":"37","author":"MD Long","year":"2013","unstructured":"Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(4):420\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"200_CR55","doi-asserted-by":"publisher","first-page":"1919-1927.e3","DOI":"10.1016\/j.cgh.2017.12.052","volume":"16","author":"Nabeel Khan","year":"2018","unstructured":"Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: A nationwide cohort study. Clin Gastroenterol Hepatol 2018. https:\/\/doi.org\/10.1016\/j.cgh.2017.12.052","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"9","key":"200_CR56","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"\u2022 Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328\u201337 This study found that younger patients with IBD have higher rates of shingles compared to older, healthy controls.","journal-title":"Arthritis Rheumatol"},{"key":"200_CR57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"\u2022 Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wklyl Rep. 2018;67:103\u20138 The updates ACIP guidelines include the use of the recombinant zoster vaccine (Shingrix) that was approved in October 2017. This recombinant vaccine can be used in immunosuppressed patients unlike the live vaccine (Zostavax) which is contraindicated in patients on high level immunosuppression.","journal-title":"MMWR Morb Mortal Wklyl Rep"},{"key":"200_CR58","first-page":"1","volume":"57","author":"R Harpaz","year":"2008","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2008;57:1\u201330.","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"200_CR59","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1097\/MIB.0000000000000743","volume":"22","author":"SK Wasan","year":"2016","unstructured":"\u2022 Wasan SK, Zullow S, Berg A, et al. Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression. Inflamm Bowel Dis. 2016;22(6):1391\u20136 This study demonstrated that while patients with IBD on low-dose immunosuppression have a reduced response to the herpes zoster vaccine, they are not at an increased risk for serious adverse events.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"200_CR60","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ijcp.12508","volume":"69","author":"SY Tsai","year":"2015","unstructured":"Tsai SY, Yang TY, Lin CL, Tsai YH, Kuo CF, Kao CH. Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015;69(2):228\u201334.","journal-title":"Int J Clin Pract"},{"issue":"RRA-4","key":"200_CR61","first-page":"1","volume":"56","author":"M Marin","year":"2007","unstructured":"Marin M, G\u00fcris D, Chaves SS, et al. Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56(RRA-4):1\u201340.","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"200_CR62","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1007\/s10620-016-4275-2","volume":"61","author":"NK Cleveland","year":"2016","unstructured":"\u2022 Cleveland NK, Rodriquez D, Wichman A, et al. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016;61(10):2972\u20136 This study was the first to assess measles immunity and the largest study to assess pertussis titers in patients with IBD. The results revealed that a significant number patients with IBD lack immunity to measles and pertussis.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"200_CR63","first-page":"1","volume":"62","author":"HQ McLean","year":"2013","unstructured":"McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2013;62(4):1\u201334.","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"200_CR64","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.dld.2017.12.027","volume":"50","author":"P Loubet","year":"2018","unstructured":"Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: results from a web-based study. Dig Liver Dis. 2018;50(6):563\u20137.","journal-title":"Dig Liver Dis"},{"key":"200_CR65","unstructured":"Cornerstones Health, Inc. IBD checklist for monitoring & prevention. Version 1.5. www.cornerstoneshealth.org\/wp-content\/uploads\/2017\/06\/Monitoring-and-Prevention-3.10.2017.pdf. Revised March 10, 2017. Accessed August 12, 2018."},{"key":"200_CR66","unstructured":"Crohn\u2019s & Colitis Foundation. Health maintenance checklist for adult IBD patients. Version 3. http:\/\/www.crohnscolitisfoundation.org\/science-and-professionals\/programs-materials\/health-maintenance-checklist.pdf. Revised January 2018. Accessed August 12, 2018."},{"issue":"9","key":"200_CR67","first-page":"1809","volume":"19","author":"S Parker","year":"2013","unstructured":"Parker S, Chambers White L, Spangler C, Rosenblum J, Sweeney S, Homan E, et al. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis. 2013;19(9):1809\u201314.","journal-title":"Inflamm Bowel Dis"},{"issue":"11 Suppl 1","key":"200_CR68","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.2146\/ajhp150094","volume":"72","author":"KG Elder","year":"2015","unstructured":"Elder KG, Lemon SK, Costello TJ. Increasing compliance with national quality measures for stroke through use of a standard order set. Am J Health Syst Pharm. 2015;72(11 Suppl 1):S6\u2013S10.","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"200_CR69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3810\/hp.2014.12.1162","volume":"42","author":"L Khoury","year":"2014","unstructured":"Khoury L, Dangodara AA, Lee JA, Lovejoy M, Amin AN. Implementation of a mandated venous thromboembolism clinical order set improves venous thromboembolism core measures. Hosp Pract (1995). 2014;42(5):89\u201399.","journal-title":"Hosp Pract (1995)"},{"issue":"1","key":"200_CR70","first-page":"90","volume":"16","author":"JR Karr","year":"2016","unstructured":"Karr JR, Lu JJ, Smith RB, Thomas AC. Using computerized physician order entry to ensure appropriate vaccination of patients with inflammatory bowel disease. Ochsner J. 2016;16(1):90\u20135.","journal-title":"Ochsner J"},{"issue":"6","key":"200_CR71","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/ecco-jcc\/jjv064","volume":"9","author":"G Malhi","year":"2015","unstructured":"Malhi G, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439\u201344.","journal-title":"J Crohns Colitis."},{"issue":"2","key":"200_CR72","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MIB.0000000000001013","volume":"23","author":"S Coenen","year":"2017","unstructured":"Coenen S, Weyts E, Jorissen C, de Munter P, Noman M, Ballet V, et al. Effects of education and information on vaccination behavior in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(2):318\u201324.","journal-title":"Inflamm Bowel Dis"},{"key":"200_CR73","doi-asserted-by":"publisher","unstructured":"Apte M, Reich J, Zahorian T, Farraye FA. Improving vaccination rates for IBD patients through the use of local pharmacies. Inflamm Bowel Dis. 2018. https:\/\/doi.org\/10.1093\/ibd\/izy209","DOI":"10.1093\/ibd\/izy209"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11938-018-0200-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:19:40Z","timestamp":1659093580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11938-018-0200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,6]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1007\/s11938-018-0200-4","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,6]]},"assertion":[{"value":"6 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Francis Farraye reports personal fees from Braintree Labs, Ferring, Janssen, and Merck and personal fees from Pfizer, Takeda, Lilly, Mesoblast, Protagonist, Theravance, and Innovation Pharmaceuticals, outside the submitted work. Jennifer Coukos declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}